scholarly journals Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

2021 ◽  
Vol 11 (7) ◽  
Author(s):  
Raquel Laza‐Briviesca ◽  
Alberto Cruz‐Bermúdez ◽  
Ernest Nadal ◽  
Amelia Insa ◽  
María del Rosario García‐Campelo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Pathological Response ◽  
Blood Biomarkers ◽  
Complete Pathological Response ◽  
Nsclc Patients

CLO19-023: Induction Chemotherapy Followed by Chemoradiation and Trans-Anal Full Thickness Local Excision or Total Mesorectal Resection in Patients With T2-T3/NO-N+ Adenocarcinoma of the Rectum; Preliminary Results of Phase 2 Prospective Clinical Trial

2019 ◽  
Vol 17 (3.5) ◽  
pp. CLO19-023
Author(s):  
Ahmed Abdalla ◽  
Amr Aref ◽  
Amer Alame ◽  
Mohamad Barawi ◽  
Danny Ma ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Neoadjuvant Therapy ◽  
Local Excision ◽  
Pathological Response ◽  
Phase Iii ◽  
Prospective Clinical Trial ◽  
Phase 2 ◽  
Full Thickness ◽  
Complete Pathological Response ◽  
Mesorectal Resection

Background: The National Comprehensive Cancer Network (NCCN) Guidelines recently recognized total neoadjuvant therapy (TNT) as an acceptable option in patients with T3 and any N rectal cancer. Previous studies suggested that patients who received chemotherapy prior to conventional preoperative chemoradiation (CRT) and surgery allowed patients to receive more of their planned treatment with a better toxicity profile and increase in pathological response. However, those studies used a long course of FOLFOX or used capecitabine and oxaliplatin as an induction regimen. We are conducting a phase 2 prospective clinical trial to evaluate the use of 6 cycles of FOLFOX as TNT in patients with T2-T3/N0-N+. Patients and Methods: Patients with T2-T3/N0-N+ enrolled on our phase 2 prospective trial were included for this analysis. Patients received 6 cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin), which was administered every 2 weeks. After 3 weeks of recovery period, patients then received conventional CRT with 5FU or capecitabine. All patients got MRI and endorectal ultrasound (ERUS) at baseline, after completing FOLFOX 3-months regimen and after finishing conventional CRT. Patients underwent either full-thickness local excision or total mesorectal resection depending on their tumor response to neoadjuvant therapy. The time interval between completion of radiation therapy and surgery ranged between 7and 12 weeks. Results: A total of 10 patients completed the chemotherapy and CRT treatment regimen. 9 patients proceeded to surgery and the 10th patient is scheduled for surgery. Clinical downstaging by MRI or ERUS was shown in 9 of 10 patients with only 6 cycles of FOLFOX. Complete clinical response was achieved in 6 patients as evident by ERUS/MRI of the pelvis after 3 months of FOLFOX before CRT. Complete pathological response was found in 4 of 9 patients (44%). In addition, 4 other patients had significant albeit not complete pathological response. Conclusions: This study suggests that adding only 6 cycles of neoadjuvant FOLFOX before CRT improved clinical and pathological downstaging of T2-T3/N0-N+ rectal adenocarcinoma and may facilitate organ preservation surgery. This is strategy needs to be investigated in larger phase III trials to validate these findings.

scholarly journals FP12.09 Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.

2021 ◽  
Vol 16 (3) ◽  
pp. S220-S221
Author(s):  
R. Laza Briviesca ◽  
E. Nadal ◽  
M. Casarrubios ◽  
A. Insa ◽  
B. Sierra-Rodero ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Pathological Response ◽  
Immune Biomarkers ◽  
Nsclc Patients ◽  
Insight Into

Complete pathological response after ceritinib for anaplastic lymphoma kinase‐rearranged epithelioid peritoneal mesothelioma

2021 ◽  
Vol 91 (3) ◽  
pp. 475-476
Author(s):  
Shinichiro Sakata ◽  
Helen Rees ◽  
Simon Parke ◽  
Norman J. Carr ◽  
Danko Kostadinov ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Pathological Response ◽  
Peritoneal Mesothelioma ◽  
Complete Pathological Response ◽  
Anaplastic Lymphoma

scholarly journals Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Rosa Montero-Macias ◽  
Meriem Koual ◽  
Céline Crespel ◽  
Marie Aude Le Frére-Belda ◽  
Hélène Blons Hélène ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Maintenance Treatment ◽  
Brca1 Mutation ◽  
Locally Advanced ◽  
Pathological Response ◽  
Advanced Cervical Cancer ◽  
Complete Pathological Response ◽  
Polymerase Inhibitors ◽  
History Of ◽  
Previously Treated

Abstract Background Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer. Case presentation Here we present the case of a patient with cervical cancer treated in this setting. A 49-year-old woman diagnosed with International Federation of Obstetricians and Gynecologists stage 2018 IIIC2 locally advanced undifferentiated cervical cancer received first-line chemoradiotherapy followed by carboplatin, paclitaxel, and bevacizumab with partial response. Because of a family history of cancers, the patient was tested and found positive for a pathogenic BRCA1 germline and somatic mutation, which motivated bevacizumab plus olaparib maintenance treatment. A simple hysterectomy was performed after 2 years stable disease; pathological report showed complete pathological response, and 12 months follow-up showed no recurrence. Conclusion Poly(ADP-ribose) polymerase inhibitors could be an alternative maintenance treatment for patients with persistent advanced cervical cancer previously treated with platinum, especially when familial history of cancers is reported. Clinical trials using poly(ADP-ribose) polymerase inhibitors for advanced cervical cancer are warranted.

Sign in / Sign up

Export Citation Format

Share Document